Core Viewpoint - RAPT Therapeutics, Inc. is actively engaging with investors through participation in multiple healthcare conferences in March 2025, highlighting its focus on immunology-based therapies for inflammatory and immunological diseases [1][3]. Company Overview - RAPT Therapeutics is a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of novel therapies aimed at treating patients with inflammatory and immunological diseases [2]. - The company leverages proprietary expertise in immunology to create therapies that modulate critical immune responses associated with these diseases [2]. Upcoming Events - RAPT Therapeutics will participate in the Leerink Global Healthcare Conference with a fireside chat scheduled for March 11, 2025, at 3:40 p.m. ET [3]. - The company will also take part in the Barclays 27th Annual Global Healthcare Conference, with a fireside chat on March 12, 2025, at 10:30 a.m. ET [3].

Core Insights - Oculis Holding AG is a global biopharmaceutical company focused on saving sight and improving eye care [3] - The company will present at the Leerink Global Healthcare Conference on March 11, 2025, at 3:00 PM ET [1] - Oculis has a differentiated pipeline including innovative product candidates such as OCS-01, OCS-05, and OCS-02 [3] Company Overview - Oculis is headquartered in Switzerland and has operations in the U.S. and Iceland [3] - The management team has a successful track record and is supported by leading international healthcare investors [3] Upcoming Events - The company will be available for one-on-one meetings during the conference, and interested investors can contact their representatives [1] - A live webcast of the fireside chat will be accessible on the Oculis website [2]

Company Overview - AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under a 351(k) biosimilar pathway [1][3] - The company is developing its proprietary product, ABP-450 (prabotulinumtoxinA) injection, targeting debilitating medical conditions, with an initial focus on the neurosciences market [3] - ABP-450 is the same botulinum toxin complex currently marketed for cosmetic use by Evolus under the name Jeuveau [3] - The product is manufactured by Daewoong in compliance with current Good Manufacturing Practice (cGMP) and has been approved by the U.S. FDA, Health Canada, and the European Medicines Agency [3] - ABP-450 is approved as a biosimilar in Mexico and India, and AEON holds exclusive development and distribution rights for therapeutic indications in the U.S., Canada, EU, UK, and other territories [3] Upcoming Events - Marc Forth, AEON's President and CEO, will present a corporate overview at the Leerink Global Healthcare Conference from March 10 to 12, 2025, in Miami, FL [1] - The corporate presentation is scheduled for March 10 at 1:00-1:30 PM ET [2]